We investigated the activity of ITF2357, a novel histone deacetylase inhibitor (HDACi) with antitumor activity, on cells carrying the JAK2(V617F) mutation obtained from polycythemia vera (PV) and essential thrombocythemia (ET) patients as well as the HEL cell line. The clonogenic activity of JAK2(V617F) mutated cells was inhibited by low concentrations of ITF2357 (IC(50) 0.001-0.01 microM),
The histone deacetylase inhibitor ITF2357 selectively targets cells bearing mutated JAK2(V617F) / Guerini, V; Barbui, V; Spinelli, O; Salvi, A; Dellacasa, C; Carobbio, A; Introna, M; Barbui, T; Golay, J; Rambaldi, A. - In: LEUKEMIA. - ISSN 1476-5551. - 22:4(2008), pp. 740-747. [10.1038/sj.leu.2405049]
The histone deacetylase inhibitor ITF2357 selectively targets cells bearing mutated JAK2(V617F)
Carobbio A;
2008
Abstract
We investigated the activity of ITF2357, a novel histone deacetylase inhibitor (HDACi) with antitumor activity, on cells carrying the JAK2(V617F) mutation obtained from polycythemia vera (PV) and essential thrombocythemia (ET) patients as well as the HEL cell line. The clonogenic activity of JAK2(V617F) mutated cells was inhibited by low concentrations of ITF2357 (IC(50) 0.001-0.01 microM),
Pubblicazioni consigliate
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris
